{"id":"conventional-fixed-dose-letrozole","safety":{"commonSideEffects":[{"rate":"19-29%","effect":"Hot flashes"},{"rate":"19-25%","effect":"Arthralgia/joint pain"},{"rate":"13-19%","effect":"Fatigue"},{"rate":"7-9%","effect":"Headache"},{"rate":"7-9%","effect":"Nausea"},{"rate":"null","effect":"Osteoporosis/bone loss"},{"rate":"null","effect":"Hypercholesterolemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Letrozole selectively inhibits aromatase, the enzyme responsible for the final step of estrogen synthesis in postmenopausal women. By reducing estrogen availability, it slows or stops the growth of estrogen-dependent breast cancer cells. This mechanism is particularly effective in hormone receptor-positive breast cancers where estrogen signaling drives tumor proliferation.","oneSentence":"Letrozole is an aromatase inhibitor that blocks the conversion of androgens to estrogen, reducing circulating estrogen levels in postmenopausal women with hormone receptor-positive breast cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:22.993Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant and metastatic settings)"},{"name":"Extended adjuvant therapy following tamoxifen in postmenopausal women with early-stage breast cancer"}]},"trialDetails":[{"nctId":"NCT07143682","phase":"PHASE3","title":"Letrozole Step up Protocol for Ovulation Induction in Infertile Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-01-08","conditions":"Polycystic Ovarian Syndrome (PCOS), Infertility","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Conventional fixed dose letrozole","genericName":"Conventional fixed dose letrozole","companyName":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","companyId":"bangabandhu-sheikh-mujib-medical-university-dhaka-bangladesh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Letrozole is an aromatase inhibitor that blocks the conversion of androgens to estrogen, reducing circulating estrogen levels in postmenopausal women with hormone receptor-positive breast cancer. Used for Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant and metastatic settings), Extended adjuvant therapy following tamoxifen in postmenopausal women with early-stage breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}